Sitagliptin: results from clinical practice

References

• American Diabetes Association. Standards of medical care in diabetes – 2011. Diabetes Care 2013;36:S11-61
   PubMed Web of Science ®Google Scholar
• Tourrel C, Bailbé D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-70
   PubMed Web of Science ®Google Scholar
• Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5’-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-55
   PubMed Web of Science ®Google Scholar
• Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-5
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-7
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P. GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. Curr Clin Pharmacol 2012;7:214-28
   PubMedGoogle Scholar
• Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012;14:350-64
   PubMed Web of Science ®Google Scholar
• Sitagliptin: European public assessment report for the public. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000722/WC500039055.pdf [Last accessed 13 August 2013]
   Google Scholar
• Sitagliptin: highlights of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021995s007lbl.pdf [Last accessed 13 August 2013]
   Google Scholar
• Aschner P, Katzeff HL, Guo H, et al.; Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-61
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-77
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-95
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 2012;98:51-60
   PubMed Web of Science ®Google Scholar
• Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol 2012; doi: 10.1111/fcp.12001
   Google Scholar
• Derosa G, D’Angelo A, Salvadeo SA, et al. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. Horm Metab Res 2010;42:8-13
   PubMed Web of Science ®Google Scholar
• Derosa G, D’Angelo A, Salvadeo SA, et al. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res 2010;79:144-9
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, D’Angelo A, et al. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. Expert Opin Pharmacother 2012;13:2433-42
   PubMed Web of Science ®Google Scholar
• Derosa G, Carbone A, D’Angelo A, et al. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. Intern Med 2013; doi: 10.2169/internalmedicine.52.8175
   Google Scholar
• Qiang D, Bo W, Yan-Jun W, et al. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin 2013;29:1487-94
   Google Scholar
• Derosa G, Maffioli P. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 2012;5:272-81
   PubMedGoogle Scholar
• Derosa G, Tinelli C, Maffioli P. Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009;11:1091-9
   PubMed Web of Science ®Google Scholar
• Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013; doi: 10.1111/dme.12144
   Google Scholar
• Questions and answers on the review of pioglitazone containing medicines. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/07/WC500109179.pdf [Last accessed 13 August 2013]
   Google Scholar
• Derosa G, Cicero AF, Franzetti IG, et al. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. Diabetes Technol Ther 2013;15:214-22
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero AF, Franzetti IG, et al. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy. Diabet Med 2013;30:846-54
   PubMed Web of Science ®Google Scholar